Sagimet Biosciences Series Stock Today
| SGMT Stock | 3.99 0.06 1.48% |
PerformanceVery Weak
| Odds Of DistressAverage
|
Sagimet Biosciences is selling for under 3.99 as of the 23rd of March 2025; that is 1.48 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 3.89. Sagimet Biosciences has over 55 % chance of experiencing financial distress in the next 2 years of operation and has generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 23rd of December 2024 and ending today, the 23rd of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 14th of July 2023 | Category Healthcare | Classification Health Care |
Sagimet Biosciences is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 30.67 M outstanding shares of which 5.47 M shares are at this time shorted by private and institutional investors with about 6.52 trading days to cover. More on Sagimet Biosciences Series
Moving together with Sagimet Stock
Moving against Sagimet Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Sagimet Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | David Happel | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsSagimet Biosciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Sagimet Biosciences' financial leverage. It provides some insight into what part of Sagimet Biosciences' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Sagimet Biosciences Series (SGMT) is traded on NASDAQ Exchange in USA. It is located in 155 Bovet Road, San Mateo, CA, United States, 94402 and employs 14 people. Sagimet Biosciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 128.46 M. Sagimet Biosciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 30.67 M outstanding shares of which 5.47 M shares are at this time shorted by private and institutional investors with about 6.52 trading days to cover.
Sagimet Biosciences generates negative cash flow from operations
Check Sagimet Biosciences Probability Of Bankruptcy
Ownership AllocationSagimet Biosciences shows a total of 30.67 Million outstanding shares. Over half of Sagimet Biosciences' outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Sagimet Ownership Details
Sagimet Biosciences Historical Income Statement
Sagimet Stock Against Markets
Sagimet Biosciences Corporate Executives
Elected by the shareholders, the Sagimet Biosciences' board of directors comprises two types of representatives: Sagimet Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sagimet. The board's role is to monitor Sagimet Biosciences' management team and ensure that shareholders' interests are well served. Sagimet Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sagimet Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lucas Pelkmans | CoFounder | Profile | |
| Urs Greber | CoFounder | Profile | |
| CPA CPA | CFO Officer | Profile | |
| Thierry Chauche | CFO Officer | Profile |
Additional Tools for Sagimet Stock Analysis
When running Sagimet Biosciences' price analysis, check to measure Sagimet Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sagimet Biosciences is operating at the current time. Most of Sagimet Biosciences' value examination focuses on studying past and present price action to predict the probability of Sagimet Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sagimet Biosciences' price. Additionally, you may evaluate how the addition of Sagimet Biosciences to your portfolios can decrease your overall portfolio volatility.